Welcome to our dedicated page for Arbutus Biopharm news (Ticker: ABUS), a resource for investors and traders seeking the latest updates and insights on Arbutus Biopharm stock.
Arbutus Biopharma Corporation (Nasdaq: ABUS) is a clinical-stage biopharmaceutical company focused on infectious disease, with a particular emphasis on chronic hepatitis B virus (cHBV) infection. The ABUS news feed highlights company announcements on clinical data, corporate strategy and intellectual property developments that shape the outlook for its pipeline and technology.
Investors and observers following ABUS news can find regular updates on imdusiran (AB-729), Arbutus’ RNAi therapeutic designed to reduce hepatitis B viral proteins and antigens including HBsAg. News items include results from Phase 1 and Phase 2a trials, such as reports of patients achieving what the company describes as functional cure, analyses of HBsAg and HBV DNA reductions, and presentations at major liver disease conferences including the European Association for the Study of the Liver (EASL) Congress and the American Association for the Study of Liver Diseases (AASLD) – The Liver Meeting.
The ABUS news stream also covers developments related to AB-101, the company’s oral PD-L1 inhibitor candidate. Releases describe safety, tolerability and pharmacodynamic findings from the ongoing Phase 1a/1b trial in healthy volunteers and cHBV patients, including data on PD-L1 receptor occupancy and the absence of AB-101-related serious adverse events reported to date.
Another recurring theme in Arbutus news is its LNP intellectual property. Joint announcements with Genevant Sciences and company updates detail U.S. and international patent infringement actions against Moderna and Pfizer/BioNTech concerning the use of LNP technology in COVID-19 vaccines. Corporate news also includes board and executive changes, restructuring actions, and strategic decisions such as reacquiring Greater China rights to imdusiran and forming a Scientific Advisory Board of cHBV experts.
For those tracking ABUS stock and the company’s progress in hepatitis B and LNP technology, this news page provides a centralized view of clinical milestones, litigation updates and corporate developments as disclosed by Arbutus in its press releases.
Arbutus Biopharma (Nasdaq: ABUS), a clinical-stage biopharmaceutical company focused on developing a functional cure for chronic hepatitis B virus (cHBV) infection, has announced its participation in the H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference. The company will present a fireside chat on October 8, 2024, at 1:30 pm ET.
Investors and interested parties can access the live webcast of the fireside chat through the Arbutus website at https://investor.arbutusbio.com/events-presentations. An archived replay of the webcast will be available on the company's website for a time after the event. Arbutus will also host one-on-one meetings during the conference.
Arbutus Biopharma (Nasdaq: ABUS), a clinical-stage biopharmaceutical company focused on developing a functional cure for chronic hepatitis B virus (cHBV) infection, has announced its participation in two upcoming investor conferences in New York:
1. H.C. Wainwright 26th Annual Global Investment Conference: Formal presentation on September 9, 2024, at 8:00 am ET
2. Baird Global Healthcare Conference: Fireside chat on September 10, 2024, at 8:30 am ET
The Arbutus management team will participate in and host one-on-one meetings at both events. Interested parties can access live webcasts of the presentation and fireside chat through the company's investor relations website. Archived replays will be available for a time after the events.
Arbutus Biopharma (ABUS) reported Q2 2024 financial results and provided updates on its hepatitis B virus (HBV) clinical programs. Key highlights include:
1. Positive data from two Phase 2a trials of imdusiran, showing 33% of patients achieved undetectable HBsAg after 48 weeks of treatment.
2. Company is prioritizing imdusiran's Phase 2b development and discontinuing HBV discovery efforts, resulting in a 40% workforce reduction.
3. Cash runway extended into Q4 2026.
4. Q2 revenue was $1.7 million, down from $4.7 million in Q2 2023.
5. Net loss of $19.8 million ($0.11 per share) compared to $17.1 million ($0.10 per share) in Q2 2023.
6. Cash, cash equivalents, and investments totaled $148.5 million as of June 30, 2024.
Arbutus Biopharma (Nasdaq: ABUS), a clinical-stage biopharmaceutical company focused on developing a functional cure for chronic hepatitis B virus (cHBV) infection, has announced the schedule for its second quarter 2024 financial results and corporate update. The company will release its Q2 2024 press release on Thursday, August 1, 2024, at 7:30 a.m. ET, followed by a conference call and webcast at 8:45 a.m. ET on the same day.
Interested parties can register for the conference call using the provided link. Additionally, a live webcast of the conference call will be accessible through the Investors section of Arbutus' website, with an archived version available after the event.
Arbutus Biopharma (Nasdaq: ABUS) has announced promising new data presented at the European Association for the Study of the Liver (EASL) Congress regarding its RNAi therapeutic, Imdusiran, combined with the T-cell stimulating immunotherapeutic VTP-300. The Phase 2a trial showed significant reductions in Hepatitis B surface antigen (HBsAg) levels. At 24-weeks post end-of-treatment, 94% of patients in the treatment arm achieved HBsAg levels <100 IU/mL, with 36% achieving <10 IU/mL. The treatment was generally safe, with no serious adverse events reported. The trial's results highlight the potential for Imdusiran and VTP-300 to enhance immune responses and reduce HBsAg in chronic hepatitis B patients.
Arbutus Biopharma (Nasdaq: ABUS) reported promising data from its Phase 2a trial (IM-PROVE I) for imdusiran in treating chronic hepatitis B virus (cHBV). Imdusiran, combined with interferon (IFN) and nucleoside analogue (NA) therapy, led to sustained undetectable HBsAg levels in 33.3% of patients (48-week imdusiran+24-week IFN) and 23.1% (24-week imdusiran+24-week IFN). Six patients remained HBsAg and HBV DNA-free off all therapy, with two maintaining this status for 12 weeks. The treatment was well-tolerated, with transient ALT elevations and injection site bruising as the most common adverse events. These results were presented at the EASL Congress 2024, showcasing imdusiran's potential for a functional cure for cHBV.
Arbutus Biopharma (Nasdaq: ABUS) announced it will participate in the Jefferies Global Healthcare Conference in New York. The company's management team is scheduled to present and hold one-on-one meetings with investors on June 5, 2024, at 9:30 am ET. Arbutus is focused on developing a functional cure for chronic hepatitis B (cHBV). A live webcast will be available, with an archived replay accessible on the Arbutus website for a time.
Arbutus Biopharma (Nasdaq: ABUS) announced that it will present data on its RNAi therapeutic, imdusiran (AB-729), at the EASL Congress 2024 from June 5-8 in Milan. Two abstracts were accepted for presentation. The first discusses the effects of imdusiran combined with pegylated interferon alfa-2a on HBeAg-negative chronic HBV patients, showing a 28% HBsAg loss in certain subjects. The second presents findings on imdusiran in combination with VTP-300, demonstrating better maintenance of lower HBV surface antigen levels compared to imdusiran alone. Both studies highlighted the safety and efficacy of imdusiran. Additional data will be shared at the conference and subsequently on Arbutus' website.
Whitefort Capital, a long-term investor and the second largest shareholder of Arbutus Biopharma (NASDAQ: ABUS), published an open letter to shareholders on May 17, 2024, outlining strategies to maximize shareholder value. Whitefort emphasizes that Arbutus' patent infringement claims against Moderna and Pfizer/BioNTech could be worth billions, urging the company to halt further share issuances to prevent dilution. They also recommend a strategic review of Arbutus' Hepatitis B Virus (HBV) portfolio by year-end, including potential licensing and collaborations. Whitefort plans to vote against proposed share increases in the company’s incentive plan, citing substantial historical dilution and unnecessary new share authorization. The company’s litigation claims, cash reserves, and upcoming clinical trial data are key focal points for future strategic decisions.
Arbutus Biopharma (Nasdaq: ABUS) will participate in two upcoming investor conferences in New York. The management team will engage in one-on-one meetings at The Citizens JMP Life Sciences Conference on May 14, 2024, and at C. Wainwright 2nd Annual BioConnect Investor Conference on May 20, 2024. Investors can access the live webcast of the fireside chats on the company's website.